Pharmaceutical-grade peptides for laboratory research, shipped worldwide in 10–14 business days.

Short amino-acid chains supplied to qualified researchers strictly for in vitro laboratory work. They are not approved for human consumption in the EU and carry no therapeutic claims.

Approved peptides hold a marketing authorization in the EU for defined therapeutic indications (e.g. semaglutide). Research peptides are sold for laboratory research only and carry no therapeutic claims.

Every compound is synthesised inside EU-based laboratories operating to GMP-aligned standards. Each batch is released only after independent third-party verification before it enters our warehouse.

A full panel: HPLC for purity, mass spectrometry for identity, LAL assay for endotoxin, bioburden plating for microbial load, water content by Karl Fischer titration, and visual inspection of the lyophilised cake. The complete panel is published on the COA for every lot.

HPLC (high-performance liquid chromatography) separates the target peptide from process impurities and quantifies each peak. ≥99% means the target compound accounts for at least 99% of the total chromatogram area, with related-substance peaks below their individual limits.

Endotoxins are bacterial cell-wall fragments that survive sterilisation and can confound research results or trigger pyrogenic responses. We test every lot with the LAL (Limulus amebocyte lysate) assay and release only batches measuring below 0.1 EU per milligram.

Yes — selected co-formulated blends are available where the literature supports a stable, well-characterised combination (e.g. BPC-157 / TB-500, CJC-1295 / Ipamorelin). Each blend ships with a single COA covering identity and purity of both compounds.

Lyophilised vials are packed in insulated mailers with phase-change gel packs and dispatched same-day from our EU warehouse. Transit is monitored end-to-end and excursion logs are available on request.